Earnings summaries and quarterly performance for DiaMedica Therapeutics.
Executive leadership at DiaMedica Therapeutics.
Board of directors at DiaMedica Therapeutics.
Research analysts who have asked questions during DiaMedica Therapeutics earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for DMAC
Also covers: AVDL, BFLY, BVS +17 more
Thomas Flaten
Lake Street Capital Markets
4 questions for DMAC
Also covers: ACHV, AQST, ASRT +13 more
MC
Matthew Caufield
H.C. Wainwright & Co., LLC
3 questions for DMAC
Also covers: MLYS, OPTN, PHAT +1 more
FB
François Brisebois
Oppenheimer & Co. Inc.
2 questions for DMAC
Also covers: ACHV, AQST, AVDL +11 more
Recent press releases and 8-K filings for DMAC.
DiaMedica Therapeutics provides DM199 preeclampsia program update
DMAC
New Projects/Investments
Guidance Update
- DiaMedica Therapeutics Inc. (DMAC) announced that the FDA requested an additional non-clinical, 10-day modified embryo-fetal development (EFD) and pre and postnatal Development (PPND) study in a rabbit model for its DM199 preeclampsia program.
- The results from this study are expected to be available by the second quarter of 2026.
- Interim data from the ongoing Phase 2 investigator-sponsored trial of DM199 in South Africa, which has dosed over 30 women, show encouraging safety and efficacy signals, including statistically significant reductions in blood pressure and dilation of intrauterine arteries.
Dec 18, 2025, 1:45 PM
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update
DMAC
New Projects/Investments
Guidance Update
- DiaMedica Therapeutics completed a pre-IND meeting with the FDA for its DM199 preeclampsia program, receiving regulatory clarity on its non-clinical package.
- The FDA requested an additional non-clinical rabbit study, with results anticipated by the second quarter of 2026.
- Interim data from an ongoing Phase 2 investigator-sponsored trial in South Africa, which has dosed over 30 women with late-stage preeclampsia, show encouraging safety and efficacy signals.
Dec 18, 2025, 1:45 PM
DiaMedica Therapeutics Reports Q3 2025 Results and Clinical Trial Updates
DMAC
Earnings
Guidance Update
New Projects/Investments
- DiaMedica Therapeutics reported cash, cash equivalents, and short-term investments of $55.3 million as of September 30, 2025, which is projected to fund planned clinical studies and corporate operations into the second half of 2027.
- The company announced positive interim results from Part 1A of its investigator-sponsored Phase 2 trial for DM199 in preeclampsia, demonstrating dose-dependent blood pressure reductions and improved placental perfusion, with DM199 not crossing the placental barrier. A U.S. Phase 2 trial for early onset preeclampsia is being prepared.
- Enrollment rates for the ReMEDy2 stroke trial are lower than initially projected, and the interim analysis based on the first 200 patients is now expected to be completed in the second half of 2026. The company is approaching 50% of its enrollment target for this analysis.
- Net losses for the third quarter of 2025 were $8.6 million and for the nine months ended September 30, 2025, were $24.0 million, representing an increase compared to the same periods in 2024.
Nov 13, 2025, 1:00 PM
DiaMedica Therapeutics Reports Q3 2025 Financial Results and Provides Business Highlights
DMAC
Earnings
Guidance Update
New Projects/Investments
- DiaMedica Therapeutics Inc. reported a net loss of $8.6 million for the third quarter ended September 30, 2025, with R&D expenses of $6.4 million and G&A expenses of $2.6 million for the same period.
- As of September 30, 2025, the company held $55.3 million in cash, cash equivalents, and investments, which is anticipated to fund operations into the second half of 2027.
- Clinical development updates include the completion of the Preeclampsia Phase 2 IST trial's Part 1a dose escalation cohort and nearing 50% enrollment for the interim analysis of the ReMEDy2 Phase 2/3 trial in Acute Ischemic Stroke, expected in 2H 2026.
Nov 12, 2025, 9:31 PM
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Clinical Trial Progress
DMAC
Earnings
Guidance Update
New Projects/Investments
- DiaMedica Therapeutics reported a net loss of $8.6 million for the third quarter ended September 30, 2025, and $24.0 million for the nine months ended September 30, 2025, driven by increased research and development (R&D) and general and administrative (G&A) expenses.
- The company's cash, cash equivalents, and investments totaled $55.3 million as of September 30, 2025, which is anticipated to provide a cash runway into the second half of 2027.
- Significant progress was made in clinical trials, including the completion of the Part 1a dose escalation cohort in the Preeclampsia Phase 2 IST Trial and the ReMEDy2 Phase 2/3 Trial for Acute Ischemic Stroke nearing 50% enrollment for its interim analysis.
Nov 12, 2025, 9:30 PM
Quarterly earnings call transcripts for DiaMedica Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more